RxDoctor Payments Data

Erin Goldman, DO

Internal Medicine · Southfield, MINPI 1548643562

Payments from drug & device makers

$952in general payments, 2019–2025

Across 16 payments — averaging $59.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$371
  • Janssen Products, LP$181
  • Gilead$132
  • Johnson & Johnson$129
  • AbbVie$121
  • Insmed, Inc.$18

What the payments were for

  • Food & beverage$89294%
  • Education$606%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company4$371
Janssen Products, LP2$181
Gilead2$132
Johnson & Johnson(2 entities)6$129
AbbVie1$121
Insmed, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$952 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$96,045
Medicare patients
277
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala87$388,315
TriumeqAbacavir/Dolutegravir/Lamivudi27$105,569
DescovyEmtricitabine/Tenofov Alafenam34$72,442
PrezcobixDarunavir/Cobicistat26$62,839
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$51,876
Isentress HdRaltegravir Potassium12$22,781
ErtapenemErtapenem Sodium12$3,027
Cefadroxil37$1,493
Cefazolin Sodium29$922
ValacyclovirValacyclovir Hcl11$614
CeftriaxoneCeftriaxone Sodium19$280
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$132$460,756121 claims
Viiv Healthcare CompanyTriumeq$371$105,56927 claims
Johnson & JohnsonPrezcobix$129$62,83926 claims
Janssen Products, LPSymtuza$181$51,87611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →